Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Trending Topics

    business

    Integration costs to continue into FY16: Sun Pharma

    Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

    first published: Jun 1, 2015 01:19 pm

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347